Vyshtakalyuk A B, Nazarov N G, Zobov V V, Semenov V E, Galyametdinova I V, Tcherepnev G V, Reznic V S
Int J Risk Saf Med. 2015;27 Suppl 1:S78-9. doi: 10.3233/JRS-150698.
Research and development of effective hepatoprotective medicines is one of the priority areas of research in Russia. Literature data shows that active research and development of hepatoprotectors is carried out both in Russian and other countries [1-6]. Pirimidines are used as hepatoprotective medicines stimulating protein synthesis and reparation of hepatocytes in toxical and infectious liver disorders [7]. In our previous work ee have shown hepatoprotective properties of pyrimidine derivative, named Xymedon [8]. This research, funded by the Russian Science Foundation, is aimed at identifying the most effective hepatoprotectors among pirimidine derivatives.
To test hepatoprotective properties of one of the new Xymedon (Xym) derivative - L-ascorbate 1-(2-hydroxyethyl)-4,6-dimethyl-1,2-dihydro-pirimidine-2-one (Asc-Xym) on the toxic liver damage model induce by carbon tetrachloride (CTC, CCl4).
The toxic liver damage in rats was modeled by subcutaneous injection of CTC (CCl4) in vegetable oil (mixed at 1:1 ratio) at a dose of 2 ml per kg. The experiments were carried out under two schemes: 1) oral administration of Xym or Asc-Xym preparations by gavage at the doses of 10 and 20 mg/kg followed by subcutaneous injection of CTC 1 hour after pyrimidine oral administration and continued for 3-4 days; - this was the design of preventive pyrimidine use, 2) liver damage modeling by CTC subcutaneous injections for 3 days followed by oral administration of Xym, Asc-Xym or Thiotriazolin (Thi) preparations at the doses of 20 mg/kg for 5 days; - this was the design of therapeutic scheme. The rats of control groups were injected with CTC according to the same schemes, but did not get any preparations. We looked at some biochemical parameters of blood serum: alanine aminotran-sferase (AlAT), aspartate aminotransferase (AsAT), their ratio (de Rytis coefficient), and the total protein level as the markers of toxic liver damage. We performed statistical data analysis by rank nonparametric Mann-Whitney U-criterion for comparison of two independent groups. We evaluated pathomorphologic characteristics of liver damage on the histological slices colored with hematoxylin and eosin.
Carbon tetrachloride (CTC) caused profound changes in the studied biochemical parameters of rats' blood serum. The AlAT activity level in the serum of control animals in the preventive scheme was 116,23 (the median) with the lower quartile and the upper quartile of 76,96 and 211,71 U/l respectively; the AsAT level was 230,08/201,49-290,03 U/l; this was the increase in comparison with the reference values. De Rytis coefficient was 1,76 /1,47-2,67. This was the decrease in comparison with the reference values of intact group (36,37/28,18-43,3 U/l; 132,95 /118,24-164,00 U/l and 4,26/3,03-5,23 respectively). The differences were statistically significant at P < 0,001. In the experimental groups the changes of the biochemical parameters with respect to the reference values were less marked than in Control. The AlAT level was 89,86/87,06-165,15; 103,23/38,19-270,87 U/l; 80,28/6,12-141,82 and 100,33/62,24-144,64 U/l in the groups of rats treated with Xym at the doses of 10 and 20 mg/kg or Asc-Xym at the doses of 10 and 20 mg/kg respectively. Similarly, in the same groups the AsAT level was 211,19/170,20-250,16; 193,61 /181,57-274,69 U/l; 190,91 /65,21-198,65 and 173,25/135,50-210,70 U/l respectively. The differences of the AsAT level were statistically significant at P < 0,05 in comparison with Control in the both groups treated with Asc-Xym.Nnearly 2 times increase of the AlAT level (67,60/1,22-94,60 U/l) (P = 0,00002) was shown in comparison with the reference values in the rats of Control group in the therapeutic scheme. However the AsAT level (163,80/130,1-178,8 U/l) was only slightly higher than reference values. De Rytis coefficient (2,07/1,78-3,48) was significantly lower than the reference values (P = 0,001). The total protein level (59,36/55,17-60,10 g/l) was lower than the reference values (65,06/62,06-68,98 g/l) by 8,4%. The differences of biochemical parameters as compared with the reference values in rats of experimental groups treated with Xym, Thi and Asc-Xym at the doses 20 mg/kg were less than those in the Control groups. They were: AlAT 52,49/44,64-62,30 and 61,42/53,20-96,66 U/l, AsAT 105,00/94,7-142,3 and 235,35/111,7-335,6 U/l, de Rytis coefficient 2,09/1,87-2,28 and 3,24/1,86-4,53, total protein 63,10/62,46-64,27 and 62,46/58,70-64,43 g/l respectively in the groups treated with Xym and Thi. The values of the studied biochemical parameters AlAT (39,04/32,46-44,24 U/l), AsAT (111,9/105,27-155 U/l), de Rytis coefficient (2,87/2,72-3,30), total protein (62,89/61,46-68,14 g/l) of the rats, treated with Asc-Xym, were the most close to the reference values in comparison with other experimental groups.The analysis of histological slices revealed large areas of steatosis and necrosis of hepatocytes in Control groups in both schemes. These were less pronounced in experimental groups than in Control groups and particularly in rats, treated with Asc-Xym.
Hepatoprtotective properties of the new compound L-ascorbate 1-(2-hydroxyethyl)-4,6-dimethyl-1,2-dihydropirimidine-2-one were established. The hepatoprotective efficacy of the compound is higher than that of Xymedon and Thiotriazolin.
研发有效的保肝药物是俄罗斯研究的重点领域之一。文献数据表明,俄罗斯和其他国家都在积极开展保肝药物的研发工作[1-6]。嘧啶类药物被用作保肝药物,可刺激蛋白质合成并修复中毒性和感染性肝病中的肝细胞[7]。在我们之前的研究中,我们已经证明了嘧啶衍生物Xymedon具有保肝特性[8]。这项由俄罗斯科学基金会资助的研究旨在确定嘧啶衍生物中最有效的保肝药物。
在四氯化碳(CTC,CCl4)诱导的肝毒性损伤模型上,测试新型Xymedon(Xym)衍生物之一——L-抗坏血酸1-(2-羟乙基)-4,6-二甲基-1,2-二氢嘧啶-2-酮(Asc-Xym)的保肝特性。
通过皮下注射按1:1比例与植物油混合的CTC(CCl4),剂量为每千克2毫升,对大鼠进行肝毒性损伤建模。实验按照两种方案进行:1)以10毫克/千克和20毫克/千克的剂量通过灌胃口服给予Xym或Asc-Xym制剂,在口服嘧啶类药物1小时后皮下注射CTC,并持续3-4天;——这是预防性使用嘧啶类药物的设计方案,2)连续3天皮下注射CTC进行肝损伤建模,随后以20毫克/千克的剂量口服给予Xym、Asc-Xym或硫代三唑啉(Thi)制剂,持续5天;——这是治疗方案的设计。对照组大鼠按照相同方案注射CTC,但不给予任何制剂。我们观察了血清中的一些生化参数:丙氨酸转氨酶(AlAT)、天冬氨酸转氨酶(AsAT)、它们的比值(德瑞蒂斯系数)以及总蛋白水平,作为肝毒性损伤的标志物。我们通过秩非参数曼-惠特尼U检验对两个独立组进行比较,进行统计数据分析。我们评估了用苏木精和伊红染色的组织切片上肝损伤的病理形态学特征。
四氯化碳(CTC)导致大鼠血清中所研究的生化参数发生显著变化。在预防性方案中,对照组动物血清中的AlAT活性水平中位数为116.23,下四分位数和上四分位数分别为76.96和211.71 U/l;AsAT水平为230.08/201.49-290.03 U/l;与参考值相比有所升高。德瑞蒂斯系数为1.76 /1.47-2.67。与完整组的参考值(分别为36.37/28.18-43.3 U/l;132.95 /118.24-164.00 U/l和4.26/3.03-5.23)相比有所降低。差异在P < 0.001时具有统计学意义。在实验组中,生化参数相对于参考值的变化比对照组小。在用10毫克/千克和20毫克/千克剂量的Xym或10毫克/千克和20毫克/千克剂量的Asc-Xym治疗的大鼠组中,AlAT水平分别为89.86/87.06-165.15;103.23/38.19-270.87 U/l;80.28/6.12-141.82和100.33/62.24-144.64 U/l。同样,在同一组中,AsAT水平分别为211.19/170.20-250.16;193.61 /181.57-274.69 U/l;190.91 /65.21-198.65和173.25/135.50-210.70 U/l。在两个用Asc-Xym治疗的组中,与对照组相比,AsAT水平差异在P < 0.05时具有统计学意义。在治疗方案中,对照组大鼠的AlAT水平(67.60/1.22-94.60 U/l)(P = 0.00002)相较于参考值显示几乎升高了2倍。然而,AsAT水平(163.80/130.1-178.8 U/l)仅略高于参考值。德瑞蒂斯系数(2.07/1.78-3.48)显著低于参考值(P = 0.001)。总蛋白水平(59.36/55.17-60.10 g/l)比参考值(65.0